

CLAIMS

1. Use of the therapeutically effective amount of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline as a partial dopamine agonist in the form of free base or in the form of pharmaceutically acceptable acid addition salt for the manufacture of a medicament for the treatment of psychostimulant addiction in humans.
2. The use according to claim 1 for inhibition or elimination of the abstinence symptoms due to withdrawal of a psychostimulant with 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of free base or in the form of pharmaceutically acceptable acid addition salt, in the individuals requiring said treatment, in the therapeutically effective amount to suppress the abstinence symptoms after withdrawal of the psychostimulant.
3. The use according to claim 1 for prevention of craving for the psychostimulant after its withdrawal with 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of free base or in the form of pharmaceutically acceptable acid addition salt, in the individuals requiring said treatment, in the therapeutically effective amount to suppress the symptoms of craving for the psychostimulant reinforcement.
4. The use according to any of claims 1 to 3, wherein the psychostimulant is selected from the group consisting of cocaine, amphetamine, methamphetamine, dextroamphetamine, 3,4-methylenedioxymethamphetamine and pemoline in the form of free base or in the form of a pharmaceutically acceptable acid addition salt.

BEST AVAILABLE COPY

5. The use of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of free base or in the form of pharmaceutically acceptable acid addition salt for the preparation of the pharmaceutical composition for the treatment of psychostimulant addiction.
6. Use of the therapeutically effective amount of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of free base or in the form of pharmaceutically acceptable acid addition salt for the manufacture of the medicament for the treatment of cocaine addiction in humans.
7. Use according to claim 6 for inhibition or elimination the abstinence symptoms due to cocaine withdrawal with 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of free base or in the form of pharmaceutically acceptable acid addition salt in the individuals requiring said treatment in the therapeutically effective amount to reduce the abstinence syndrome after cocaine withdrawal.
8. The use according to claim 6 for prevention of cocaine-seeking after its withdrawal with 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of free base or in the form of pharmaceutically acceptable acid addition salt in the individuals requiring said treatment in the therapeutically effective amount to suppress the symptoms of craving for the psychostimulant reinforcement.
9. The use according to any of claims 6 to 8, wherein 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline is the form of bimalate salt.
10. The use according to any of claims 6 to 9, wherein the daily dose of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the

BEST AVAILABLE COPY

form of a free base or in the form of pharmaceutically acceptable acid addition salt ranges from 0.05 to 20 mg.

11. The use according to claim 10, wherein the dose unit of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of free base or in the form of pharmaceutically acceptable acid addition salt is from 0.1 to 5.0 mg.
12. A pharmaceutical composition comprising from 0.05 to 20 mg of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of free base or in the form of pharmaceutically acceptable acid addition salt and a pharmaceutically acceptable carrier, wherein said pharmaceutical composition is used for the treatment of cocaine addiction in cocaine addicts.
13. The pharmaceutical composition according to claim 12 comprising from 0.1 to 5.0 mg of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of free base or in the form of pharmaceutically acceptable acid addition salt and a pharmaceutically acceptable carrier.
14. The use of 9,10-didehydro-N-methyl-N-(2-propynyl)-6-methyl-8 β -aminomethylergoline in the form of free base or in the form of pharmaceutically acceptable acid addition salt as a partial dopamine agonist for the preparation of the pharmaceutical composition for the treatment of cocaine addiction.

BEST AVAILABLE COPY